Log In
Print
BCIQ
Print
Print this Print this
 

Shigamabs (caStx1, caStx2)

  Manage Alerts
Collapse Summary General Information
Company Bellus Health Inc.
DescriptionChimeric mAbs caStx1 and caStx2 against Shiga toxin
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationEscherichia
Indication DetailsTreat Shiga toxin-producing Escherichia coli (STEC) infections
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$13.8M

$6.1M

$7.7M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today